Propofol 2%: understanding a new concentration of a well-known medication

Regier, Betsy A.; Meyer, Tricia A.; McAllister, Russell K.

doi:10.1080/08998280.2021.1937009

Cited by 1 publication

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…That study reported 25 deaths at 28 days, 21 of which were receiving propofol [9]. Of those 21 subjects, 12 were receiving the 2% formulation which is not traditionally used in the United States, last in 2021 during an emergency use authorization by the FDA during a propofol 1% critical shortage [11]. Additionally, 10 of the 21 deaths at 28 days were recorded at one center.…”

Section: Introductionmentioning

confidence: 99%

Safety of Extended Propofol Infusions in Critically Ill Pediatric Patients

Moas,

Aydin,

Irazuzta

et al. 2024

Cureus

View full text Add to dashboard Cite

IntroductionPropofol is a phenol agent with sedative and anesthetic properties that has been in use for decades, but with controversy in critically ill pediatric patients, given the concern for developing propofol-related infusion syndrome (PRIS). Our aim was to assess the risk of propofol infusions in the pediatric intensive care unit (PICU) at doses and durations greater than the described safety data and its associated covariables. MethodsRetrospective cohort analysis of 173 patients receiving propofol in the PICU. Patients were categorized as receiving greater or less than 48-hour infusions. Demographic data and daily clinical variables were recorded for up to seven days post-infusion initiation or until infusion was stopped. ResultsIn this descriptive analysis, patients' demographics were similar, but admission diagnosis was not. Both groups received high mean doses of propofol (>67 mcg/kg/min), with no cases of PRIS observed. The illness severity scores and the need for vasoactive infusion support varied between the cohorts, with higher illness scores and a higher percentage of subjects requiring vasoactive agents in the >48-hour cohort. Finally, there were no major differences in lactate levels or biochemical characteristics between the two groups. ConclusionsThis study provides pilot data in relation to the feasibility of propofol infusion in critically ill pediatric patients and underscores the need for a larger multicenter study to draw clinical recommendations.

show abstract

Section: Introductionmentioning

confidence: 99%